Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO – Research Report) and Ramsay Health Care (RMSYF – Research Report).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bio-Rad Laboratories (BIO)
RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories on June 5 and set a price target of $381.00. The company’s shares closed last Monday at $225.56.
According to TipRanks.com, McNamara ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $316.40 average price target.
See today’s best-performing stocks on TipRanks >>
Ramsay Health Care (RMSYF)
In a report released today, Steven Wheen from Jarden maintained a Hold rating on Ramsay Health Care, with a price target of A$44.05. The company’s shares closed last Thursday at $24.00.
According to TipRanks.com, Wheen is ranked #1103 out of 9627 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $25.09 average price target.
Read More on BIO:
